Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 08, 2026
DataAggregated Company Financials
Companies147
  • 7D0.8%
  • 3M-5.9%
  • 1Y4.8%
  • YTD-3.2%

The Healthcare is pretty flat in the last 7 days, but Sectra has stood out, gaining 3.9%. The past year has been better, since the industry has gained 4.8% in that time. As for the next few years, earnings are expected to grow by 24% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 08 Apr 2026SEK 565.0bSEK 229.1b-SEK 2,922,110,742.8131.3x-193.4x2.5x
Fri, 06 Mar 2026SEK 549.9bSEK 229.0b-SEK 2,476,323,659.3030.5x-222.1x2.4x
Sun, 01 Feb 2026SEK 582.1bSEK 228.9bSEK 3.3b37.5x176.5x2.5x
Tue, 30 Dec 2025SEK 589.4bSEK 230.5bSEK 3.6b42.6x161.5x2.6x
Thu, 27 Nov 2025SEK 601.8bSEK 230.8bSEK 3.2b42.5x186.2x2.6x
Sat, 25 Oct 2025SEK 614.4bSEK 228.3bSEK 3.1b48.6x200.7x2.7x
Mon, 22 Sep 2025SEK 618.8bSEK 227.4bSEK 6.6b46x93.8x2.7x
Wed, 20 Aug 2025SEK 617.8bSEK 227.1bSEK 6.5b44.4x95x2.7x
Fri, 18 Jul 2025SEK 634.7bSEK 227.8bSEK 6.6b44.9x96.8x2.8x
Sun, 15 Jun 2025SEK 603.9bSEK 226.4bSEK 5.8b40.1x103.6x2.7x
Tue, 13 May 2025SEK 605.2bSEK 224.0bSEK 5.2b35.4x115.7x2.7x
Thu, 10 Apr 2025SEK 507.2bSEK 221.4bSEK 5.4b30.1x93.3x2.3x
Sat, 08 Mar 2025SEK 557.2bSEK 205.9bSEK 4.7b36x118.3x2.7x
Mon, 03 Feb 2025SEK 602.2bSEK 204.1bSEK 1.5b43.6x394.3x2.9x
Wed, 01 Jan 2025SEK 581.6bSEK 202.6b-SEK 2,502,931,625.7039x-232.4x2.9x
Fri, 29 Nov 2024SEK 516.4bSEK 199.4b-SEK 2,982,923,794.2636.4x-173.1x2.6x
Sun, 27 Oct 2024SEK 597.4bSEK 201.8b-SEK 2,327,827,882.9739.7x-256.6x3x
Tue, 24 Sep 2024SEK 615.2bSEK 200.1b-SEK 2,816,505,402.9141.3x-218.4x3.1x
Thu, 22 Aug 2024SEK 593.3bSEK 199.9b-SEK 1,827,902,985.6441.5x-324.6x3x
Sat, 20 Jul 2024SEK 590.0bSEK 198.0b-SEK 2,773,387,911.6143.5x-212.7x3x
Mon, 17 Jun 2024SEK 555.8bSEK 195.5b-SEK 3,170,352,917.2135.3x-175.3x2.8x
Wed, 15 May 2024SEK 556.2bSEK 196.7b-SEK 2,686,914,216.2136.1x-207x2.8x
Fri, 12 Apr 2024SEK 524.1bSEK 192.7b-SEK 3,173,168,722.5145.1x-165.2x2.7x
Sun, 10 Mar 2024SEK 525.5bSEK 192.1b-SEK 3,679,319,655.6243.5x-142.8x2.7x
Tue, 06 Feb 2024SEK 516.0bSEK 188.9b-SEK 4,141,640,228.2549.4x-124.6x2.7x
Thu, 04 Jan 2024SEK 537.0bSEK 191.4b-SEK 966,531,651.0046.9x-555.6x2.8x
Sat, 02 Dec 2023SEK 502.0bSEK 190.5b-SEK 1,082,699,817.0052.1x-463.6x2.6x
Mon, 30 Oct 2023SEK 430.6bSEK 188.4b-SEK 1,511,030,224.0032x-284.9x2.3x
Wed, 27 Sep 2023SEK 447.2bSEK 185.2b-SEK 2,036,963,813.0035.5x-219.5x2.4x
Fri, 25 Aug 2023SEK 458.4bSEK 185.1b-SEK 1,828,666,862.0038.7x-250.7x2.5x
Sun, 23 Jul 2023SEK 478.1bSEK 182.8b-SEK 1,004,494,296.0041.5x-476x2.6x
Tue, 20 Jun 2023SEK 496.7bSEK 179.2b-SEK 777,627,020.0045.7x-638.7x2.8x
Thu, 18 May 2023SEK 519.0bSEK 177.1b-SEK 863,515,969.0042.5x-601x2.9x
Sat, 15 Apr 2023SEK 513.9bSEK 172.6b-SEK 1,425,668,652.0035.8x-360.4x3x
Price to Earnings Ratio

-360.4x


Total Market Cap: SEK 513.9bTotal Earnings: -SEK 1,425,668,652.00Total Revenue: SEK 172.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -163x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market1.06%
Healthcare0.82%
Healthtech3.31%
Life Sciences2.57%
Medical Equipment1.26%
Biotech0.27%
Healthcare Services0.066%
Pharma-0.41%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SECT B SectraSEK 235.003.9%
+SEK 1.7b		-4.2%PE84.2x
BONEX Bonesupport HoldingSEK 215.0010.3%
+SEK 1.3b		-31.0%PE101x
IMP A SDB ImplanticaSEK 47.956.7%
+SEK 850.0m		68.2%PS596.2x
VIMIAN Vimian GroupSEK 29.103.9%
+SEK 582.2m		-28.1%PE44.8x
ATT AttendoSEK 105.103.9%
+SEK 563.5m		80.9%PE18.7x

Latest News

MCOV B
SEK 186.80
Medicover
7D
-0.7%
1Y
-5.0%

MCOV B: Dividend Growth And 2028 Revenue Ambitions Will Support Upside

Analysts have nudged their Medicover price target higher to SEK227.29 from SEK225.05, citing updated assumptions that reflect a slightly higher discount rate, along with revised expectations for revenue growth, profit margins and future P/E. What's in the News The board proposes a dividend of €0.20 per share for the 2025 financial year, compared with €0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
ATT
SEK 105.10
Attendo
7D
3.9%
1Y
80.9%
SECT B
SEK 235.00
Sectra
7D
3.9%
1Y
-4.2%

SECT B: Cloud Contracts And Rating Upgrades Will Shape Future Return Balance

Analysts have maintained the fair value estimate for Sectra at SEK 227.50. Recent upgrades and new price targets, which range from SEK 210 to SEK 250, support a slightly lower implied discount rate and marginally adjusted long-term growth and P/E assumptions.
BIOG B
SEK 117.90
BioGaia
7D
-1.3%
1Y
16.6%

BIOG B: Downgrade And Extra Dividend Will Set Up Future Multiple Re Rating

Analysts have trimmed their stance on BioGaia with a lower SEK price target, reflecting more cautious views on the shares following a downgrade from SEB Equities and only slight adjustments to assumptions such as the discount rate and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the trimmed price target and modest changes to the discount rate and future P/E as leaving room for upside if execution on growth initiatives tracks current expectations.
VIMIAN
SEK 29.10
Vimian Group
7D
3.9%
1Y
-28.1%

VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential

Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.
EKTA B
SEK 54.00
Elekta
7D
-2.2%
1Y
13.7%

EKTA B: Future Outlook Balances Mixed Ratings With Product Adoption Progress

Analysts lifted their fair value estimate for Elekta to SEK 58.27 from SEK 56.77, reflecting a higher assumed future P/E and recent Street research, where one firm raised its price target to SEK 60 while another turned more cautious on the shares. Analyst Commentary Bullish Takeaways Bullish analysts see the higher SEK 60 price target as better aligned with the updated fair value estimate, which now builds in a higher assumed P/E multiple.
HNSA
SEK 29.80
Hansa Biopharma
7D
-6.5%
1Y
32.3%

HNSA: U.S. Kidney Transplant Approval Pathway Will Drive Potential Upside

Analysts have adjusted their price target on Hansa Biopharma by SEK 8, reflecting updated views on the risk profile and near term commercial opportunity for imlifidase, including its potential positioning in kidney transplantation and autoimmune indications. Analyst Commentary Recent research shows a mix of optimism and caution around Hansa Biopharma, with views shaped by the commercial outlook for imlifidase in kidney transplantation and autoimmune indications, as well as how quickly the company can execute on its plans.
BONEX
SEK 215.00
Bonesupport Holding
7D
10.3%
1Y
-31.0%
GETI B
SEK 190.00
Getinge
7D
0.8%
1Y
1.0%

Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next

Mar 29
Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
BIOA B
SEK 314.00
BioArctic
7D
-1.9%
1Y
84.3%
ASKER
SEK 67.90
Asker Healthcare Group
7D
-1.9%
1Y
-11.8%
ALIF B
SEK 143.80
AddLife
7D
3.1%
1Y
-1.1%

ALIF B: Higher Margin Outlook And Dividend Policy Will Support Future Upside

Analysts have trimmed their price target for AddLife from SEK191.50 to SEK187.50, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E levels. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.5000 per share, with an ex date on May 7, 2026, a record date on May 8, 2026, and a payment date on May 13, 2026 (Key Developments).
XSPRAY
SEK 26.25
Xspray Pharma
7D
-11.6%
1Y
-5.6%
XVIVO
SEK 241.00
Xvivo Perfusion
7D
5.2%
1Y
-12.3%

XVIVO: Higher Margins And Discount Assumptions Will Support Future Upside Potential

Analysts have modestly reduced their price target for Xvivo Perfusion to SEK245. This reflects slightly higher discount rate assumptions alongside small adjustments to revenue growth, profit margin, and future P/E expectations.
FLERIE
SEK 29.50
Flerie
7D
-19.0%
1Y
-28.0%
IMP A SDB
SEK 47.95
Implantica
7D
6.7%
1Y
68.2%